Why the study?
Are HER2-targeted therapies safe to administer in patients with HER2-positive breast cancer and reduced LVEF when receiving cardioprotective medications and close cardiac monitoring?
Are HER2-targeted therapies safe to administer in patients with HER2-positive breast cancer and reduced LVEF when receiving cardioprotective medications and close cardiac monitoring?
HER2-targeted therapies can be safely administered to breast cancer patients with reduced LVEF through multidisciplinary cardio-oncology collaboration and cardioprotective medical therapy.
Supports HER2 therapy in reduced LVEF with monitoring; leaves open confirmation in larger trials.
This study provides safety data of HER2-targeted therapies in patients with breast cancer and reduced LVEF while receiving cardioprotective medications and close cardiac monitoring. Our results demonstrate the importance of collaboration between cardiology and oncology providers to allow for delivery of optimal oncologic care to this unique population.
No takes yet. Share an insight, caveat, or question.
Lynce et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: